Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
12 min read
Stenosis, Pulmonary Vein Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Stenosis, Pulmonary Vein in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Cutis Laxa Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Cutis Laxa with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
46, XX Disorders of Sex Development Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate 46, XX Disorders of Sex in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
3-Methylglutaconic Aciduria Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate 3-Methylglutaconic Aciduria in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Familial Anomalous Origin of Right Pulmonary Artery Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Familial Anomalous Origin of in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Obesity, Abdominal Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Obesity, Abdominal with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Anemia, Aplastic Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Anemia, Aplastic with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
10 min read
Chengdu Kanghong Pharmaceutical Group Co., Ltd Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
18 August 2026
A 2026 BD opportunity scan of Chengdu Kanghong Pharmaceutical Group Co., Ltd, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.
Latest Hotspot
9 min read
ASKA Pharmaceutical Co, Ltd Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
18 August 2026
A 2026 BD opportunity scan of ASKA Pharmaceutical Co, Ltd, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.
Latest Hotspot
10 min read
Asahi Kasei Therapeutics Corporation. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
18 August 2026
A 2026 BD opportunity scan of Asahi Kasei Therapeutics Corporation., covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.
Latest Hotspot
10 min read
Chengdu Brilliant Pharmaceutical CO., LTD. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
18 August 2026
A 2026 BD opportunity scan of Chengdu Brilliant Pharmaceutical CO., LTD., covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.
Latest Hotspot
10 min read
Ferring Pharmaceuticals Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
18 August 2026
A 2026 BD opportunity scan of Ferring Pharmaceuticals, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.